Author
Mark Deakin
Other affiliations: Royal Stoke University Hospital, Keele University
Bio: Mark Deakin is an academic researcher from Edinburgh Napier University. The author has contributed to research in topics: Smart city & Urban planning. The author has an hindex of 30, co-authored 124 publications receiving 3481 citations. Previous affiliations of Mark Deakin include Royal Stoke University Hospital & Keele University.
Papers published on a yearly basis
Papers
More filters
••
TL;DR: A bibliometric analysis of the literature published between 1992 and 2012 shows that smart-city research is fragmented and lacks cohesion, and its growth follows two main development paths.
Abstract: This paper reports on the first two decades of research on smart cities by conducting a bibliometric analysis of the literature published between 1992 and 2012. The analysis shows that smart-city r...
392 citations
••
TL;DR: In this paper, the authors demonstrate how the triple-helix model enables us to study the knowledge base of an urban economy in terms of its civil society's support for the evolution of the city as a key component of an innovation system.
Abstract: This paper sets out to demonstrate how the triple-helix model enables us to study the knowledge base of an urban economy in terms of its civil society's support for the evolution of the city as a key component of an innovation system. It argues that cities can be considered as densities in networks among three relevant dynamics: the intellectual capital of universities, the wealth creation of industries, and the democratic government of civil society. It goes on to suggest that these interactions generate dynamic spaces within cities where knowledge can be exploited to bootstrap the technology of regional innovation systems. These dynamic spaces can best be understood as spaces of ubiquitous information and communication technologies (ICT) where knowledge is key to regional innovation systems, creating the notion of “smart cities.”
321 citations
••
University of Liverpool1, University Hospitals Birmingham NHS Foundation Trust2, Uppsala University3, University of Alberta4, Princess Margaret Cancer Centre5, University of Manchester6, Beatson West of Scotland Cancer Centre7, University of Paris8, Glasgow Royal Infirmary9, University of Melbourne10, University of New South Wales11, University of Sydney12, Freeman Hospital13, University of Oxford14, St James's University Hospital15, Greifswald University Hospital16, Semmelweis University17, University of Verona18, Heidelberg University19
TL;DR: Subject to prospective validation, gemcitabine should not be used for patients with low tumor hENT1 expression.
Abstract: Background Human equilibrative nucleoside transporter 1 (hENT1) levels in pancreatic adenocarcinoma may predict survival in patients who receive adjuvant gemcitabine after resection. Methods Microarrays from 434 patients randomized to chemotherapy in the ESPAC-3 trial (plus controls from ESPAC-1/3) were stained with the 10D7G2 anti-hENT1 antibody. Patients were classified as having high hENT1 expression if the mean H score for their cores was above the overall median H score (48). High and low hENT1-expressing groups were compared using Kaplan-Meier curves, log-rank tests, and Cox proportional hazards models. All statistical tests were two-sided. Results Three hundred eighty patients (87.6%) and 1808 cores were suitable and included in the final analysis. Median overall survival for gemcitabine-treated patients (n = 176) was 23.4 (95% confidence interval [CI] = 18.3 to 26.0) months vs 23.5 (95% CI = 19.8 to 27.3) months for 176 patients treated with 5-fluorouracil/folinic acid (months vs 23.5 (95% CI = 19.8 to 27.3) months for 176 patients treated with 5-fluorouracil/folinic acid (chi(2)(1)=0.24; P = .62). Median survival for patients treated with gemcitabine was 17.1 (95% CI = 14.3 to 23.8) months for those with low hENT1 expression vs 26.2 (95% CI = 21.2 to 31.4) months for those with high hENT1 expression (chi(2)(1)=9.87; P = .002). For the 5-fluorouracil group, median survival was 25.6 (95% CI = 20.1 to 27.9) and 21.9 (95% CI = 16.0 to 28.3) months for those with low and high hENT1 expression, respectively (chi(2)(1) = 0.83; P = .36). hENT1 levels were not predictive of survival for the 28 patients of the observation group (chi(2)(1) = 0.37; P = .54). Multivariable analysis confirmed hENT1 expression as a predictive marker in gemcitabine-treated (Wald chi(2)(1) = 9.16; P = .003) but not 5-fluorouracil-treated (Wald chi(2)(1) = 1.22; P = .27) patients. Conclusions Subject to prospective validation, gemcitabine should not be used for patients with low tumor hENT1 expression.
298 citations
••
TL;DR: In this paper, the authors examine the methodological issues that smart communities pose cities and the critically insightful role which the networks of innovation and creative partnerships set up to embed such intelligence play in the learning, knowledge transfer and capacity-building exercises servicing this community-led transition to smart cities.
Abstract: Taking Hollands' previous statement on the transition from intelligent to smart cities as its point of departure (‘Will the real smart city stand up?’ City 12(3), 302–320), this article reflects upon the anxieties currently surrounding such developments. In particular, it considers the suggestion that such developments have more to do with cities meeting the corporate needs of marketing campaigns than the social intelligence required for them to be smart. Focusing on the social intelligence of such developments, this article captures the information-rich and highly communicative qualities of the transition. In particular, it examines the methodological issues that smart communities pose cities and the critically insightful role which the networks of innovation and creative partnerships set up to embed such intelligence play in the learning, knowledge transfer and capacity-building exercises servicing this community-led transition to smart cities. This, the article suggests, is what existing representation...
262 citations
••
TL;DR: The results of this best practice analysis offer a series of critical insights into what strategic principles drive smart city development in Europe and generate scientific knowledge which helps to overcome the dichotomous nature of smart city research.
207 citations
Cited by
More filters
03 May 2018
2,508 citations
••
TL;DR: The different metrics of urban smartness are reviewed to show the need for a shared definition of what constitutes a smart city, what are its features, and how it performs in comparison to traditional cities.
Abstract: As the term “smart city” gains wider and wider currency, there is still confusion about what a smart city is, especially since several similar terms are often used interchangeably. This paper aims to clarify the meaning of the word “smart” in the context of cities through an approach based on an in-depth literature review of relevant studies as well as official documents of international institutions. It also identifies the main dimensions and elements characterizing a smart city. The different metrics of urban smartness are reviewed to show the need for a shared definition of what constitutes a smart city, what are its features, and how it performs in comparison to traditional cities. Furthermore, performance measures and initiatives in a few smart cities are identified.
2,207 citations
•
TL;DR: The process of innovation must be viewed as a series of changes in a complete system not only of hardware, but also of market environment, production facilities and knowledge, and the social contexts of the innovation organization as discussed by the authors.
Abstract: Models that depict innovation as a smooth, well-behaved linear process badly misspecify the nature and direction of the causal factors at work. Innovation is complex, uncertain, somewhat disorderly, and subject to changes of many sorts. Innovation is also difficult to measure and demands close coordination of adequate technical knowledge and excellent market judgment in order to satisfy economic, technological, and other types of constraints—all simultaneously. The process of innovation must be viewed as a series of changes in a complete system not only of hardware, but also of market environment, production facilities and knowledge, and the social contexts of the innovation organization.
2,154 citations
01 Jan 2008
TL;DR: In this article, the authors argue that rational actors make their organizations increasingly similar as they try to change them, and describe three isomorphic processes-coercive, mimetic, and normative.
Abstract: What makes organizations so similar? We contend that the engine of rationalization and bureaucratization has moved from the competitive marketplace to the state and the professions. Once a set of organizations emerges as a field, a paradox arises: rational actors make their organizations increasingly similar as they try to change them. We describe three isomorphic processes-coercive, mimetic, and normative—leading to this outcome. We then specify hypotheses about the impact of resource centralization and dependency, goal ambiguity and technical uncertainty, and professionalization and structuration on isomorphic change. Finally, we suggest implications for theories of organizations and social change.
2,134 citations
••
University of Liverpool1, Royal Liverpool University Hospital2, Clatterbridge Cancer Centre NHS Foundation Trust3, University of Manchester4, Manchester Royal Infirmary5, The Royal Marsden NHS Foundation Trust6, Weston Park Hospital7, Royal Free Hospital8, St James's University Hospital9, Karolinska Institutet10, Uppsala University11, University of Hamburg12, Royal Surrey County Hospital13, Guy's Hospital14, Hammersmith Hospital15, Beatson West of Scotland Cancer Centre16, Cardiff University17, Queen Elizabeth Hospital Birmingham18, Churchill Hospital19, Derriford Hospital20, University Hospital Coventry21, Heidelberg University22
TL;DR: The adjuvant combination of gem citabine and capecitabine should be the new standard of care following resection for pancreatic ductal adenocarcinoma.
1,378 citations